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Abstract
Dr. Saul Hertz spontaneously posed the question "Could iodine be made radioactive
artificially?" to the MIT President Karl Compton, on November 12, 1936. MGH's Dr.
Hertz and his MIT collaborator, Dr. Arthur Roberts, were the first and the foremost to
develop the experimental data for the medical uses of radioiodine (RAI) and apply it in
the clinical setting. Dr. Hertz expanded the successful use of RAI of treating hyperthyr‐
oidism, Graves‘ disease, to the treatment of thyroid cancer in 1946. Dr. Saul Hertz
established the Radioactive Isotope Research Institute to diagnose and treat thyroid
cancer, which he believed held the key to the larger problem of cancer in general. RAI
is the first and gold standard of targeted cancer therapies.
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1. Seminal question
Dr. Saul Hertz (Figure 1) attended a luncheon meeting at Harvard Medical School’s Vander‐
bilt Hall on November 12, 1936 (Figure 2). Karl T. Compton, the President of Massachusetts
Institute of Technology (MIT), was speaking on the topic “What Physics Can Do for Biology and
Medicine.”
Dr. Hertz, who was the director of the Thyroid Clinic (1931–1943) at Massachusetts General
Hospital (MGH), asked President Compton the seminal question, “Could iodine be made
radioactive artificially?” Hertz had been conducting studies on the use of iodine and its effect
on thyroid function. Hertz’s question came spontaneously as documented in MGH’s Dr. James
Means’s letter (Figure 3) to Archie Woods of the Mary and John Markle Foundation that
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sponsored the building of the MIT Cyclotron. Dr. Arthur Roberts, Dr. Hertz’s MIT collabora‐
tor, wrote to Dr. John Stanbury, the author of A Constant Ferment: A History of MGH Thyroid
Clinic and Laboratory at The Massachusetts General Hospital: 1913–1990, as Stanbury was
developing his book. Dr. Roberts in his letter dated April 3, 1991, states “Your conjecture that
it was the outcome of a group discussion has no basis in fact.” Stanbury’s book has been in
publication for many decades and has been used as a citation with false information (Fig‐
ure 4a–c).
Figure 1. Mallinckrodt, a $2.1 billion global pharmaceutical company honors Dr Saul Hertz's discovery of the medical
uses of radioiodine (RAI).
Figure 2. Harvard Medical School's Vanderbilt Hall the site of Dr Hertz spontaneously asking MIT's President Karl
Compton, “Could iodine be made radioactive artificially?”.
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Figure 3. MGH's Chief of Medicine's letter to the Markle Foundation documenting Dr Hertz's spontaneous seminal
question that launched the RAI breakthrough research.
Dr. Hertz’s seminal question brought together the work established in 1896 of E. Bauman’s
reporting the effect of iodine on the functioning of the thyroid. Bauman found high concen‐
trations of iodine tightly bound to proteins in extracts of the thyroid gland, thyroid extracts
were standardized to contain 0.2% iodine in order to maintain equal potency of different
preparations. Additionally, in the field of radioactivity, in 1896 Henri Becquerel investigated
the newly discovered X-rays that led to studies of how uranium salts are affected by light. Saul
Hertz’s seminal question brought together the effect of iodine on the thyroid and radioactivity.
Hertz’s question launched the radioactive iodine (RAI) research that established the corner‐
stone of Nuclear Medicine.
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Figure 4. (a–c) Pivitol letter from MIT's Dr Arthur Roberts to the author of A Constant Ferment, of which the author, Dr
John Stanbury, chose to ignore.
2. Rabbit studies
In early 1937, the collaboration was established between the Massachusetts Institute of
Technology and Boston’s Massachusetts General Hospital. The young physicist Dr. Arthur
Roberts was hired by MIT, and MGH’s Dr. Saul Hertz began the first studies on rabbits to
evaluate the effects of a nuclear substance, radioactive iodine, on the thyroid. Dr. Roberts
produced noncyclotron I-128 in small quantities based on Fermi’s work. The experiment
involved 48 rabbits. The RAI was administered to rabbits with altered thyroid function.
Quantitative analysis showed that hyperplastic thyroid glands retained more RAI than normal
thyroid glands. The studies demonstrated the principle that tracer amounts of radioactive
iodine could be used to investigate thyroid gland physiology demonstrating the tracer
capabilities of RAI and its effects on the thyroid gland (Figure 5).
The original draft of the article describing their rabbit study findings had Hertz and Roberts
as the coauthors as they had done the work and written the paper. MIT’s Robley Evans, who
was the administrator of the lab at MIT and who had hired the physicist Arthur Roberts,
insisted that his name be added to the paper while it was at the publishers. Robley Evans had
done no work in the construction of the experiment, analysis of the data, or writing the paper
(Figure 4a–c). When Roberts was hired Evans had included a condition of his employment,
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that his (Evans) name be added to any papers that might be forthcoming. Evans dictated a
letter to the editor for Hertz to sign that Robley Evans’s name be added although Evans made
no contribution.
Figure 5. MIT's Dr Arthur Roberts (left) MGH's Dr Saul Hertz (right) administering non cyclotron produced I-128.
These studies demonstrated the principle of using a radioactive substance as a tracer.
Hertz and Roberts were hopeful that they could go from diagnosis to treatment; however, they
knew that they would need a larger quantity of RAI with a longer half-life. Cyclotron-produced
RAI was needed. MGH’s Chief of Medicine, Dr. James H. Means, took the train from Boston
to New York City and secured a $30,000.00 check from the Mary and John Markel Foundation
for the building of MIT’s Cyclotron.
2.1. The first therapeutic use of RAI
The new Markel MIT Cyclotron, the first built exclusively for medical purposes, began
operations in late 1940. Most of the RAI produced by this cyclotron was I-130 that has a half-
life of 12 hours. Another 10% of the cyclotron product was I-131. Dr. Hertz administered the
first therapeutic treatment of RAI on March 31, 1941 to Elizabeth D. at the Massachusetts
General Hospital. Noted on Hertz’s Data Charts (Figure 6a and b) was that this first patient
received 2.1 mCi (77.7 MBq) of I-130 because its radiation was delivered rapidly to the thyroid
cells over a day or two.
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Figure 6. (a and b) Dr Hertz's handwritten Data Charts (1941–1946) of the very first series of patients treated success‐
fully with a radioactive substance, RAI.
Dr. Hertz and his MIT collaborator Dr. Arthur Roberts continued to treat about one new patient
per month for the rest of 1941. The total estimated RAI given to each of the eight patients ranged
from 55 to 230 MBq with an average of 144 MBq. RAI was taken up by the patient’s thyroid
glands, and the patients did in fact get better. Hertz gave each patient a stable iodine beginning
1–3 days after the radioiodine at the insistence of his chief Dr. James Means. Means wanted to
protect the patients against thyroid storm in case the RAI therapy was not effective. At the
American Society for Clinical Investigation Meeting in May, 1942, Hertz presented a series of
eight patients treated with RAI he had followed for at least 3 months; according to the abstract
there were both “failures and successes.”
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Figure 7. Cleveland Press Newspaper headline. Dr Hertz was born and grew up in Cleveland, Ohio.
Hertz continued to treat hyperthyroid patients with I-130 throughout 1942. In January 1943,
Dr. Hertz joined the United States Navy to serve his country during World War II. MGH’s Dr.
Earl Chapman was Four “F” and was ineligible for service. Chapman, a private practice doctor
who treated Boston’s Beacon Hill-style affluent patients managed to carry on clinical research
and worked part-time at MGH. Hertz asked Chapman to take over his RAI cases, in that he
felt he (Hertz) had firmly established the work. Dr. Leonard Wartofsky stated “Chapman was
probably honored to get involved in some clinical research and take on these patients [1].”
Chapman saw an opportunity. Dr. Arthur Roberts, Hertz’s MIT collaborator, writes “I would
believe nothing on this subject from Chapman, whose self-interest is obvious and who bungled
—whether deliberately or not—the follow-up on Hertz’s original series when Hertz joined the
Navy.” Yes, Chapman tweaked the protocol and the letters between Hertz and Chapman
during the war years produced tension. In March of 1946, at the end of World War II, Hertz
received a cold reception at MGH. His service to his country was not honored. In Boston, The
Beth Israel Hospital was emerging and welcoming “outsiders” to the establishment to be on
staff. Although there remained quotas at medical schools, “Jews” were being trained and
needed a place to practice. Dr. Hertz joined the staff of The Beth Israel Hospital.
Meanwhile, Chapman had established 22 patients of his own along with MIT’s Robley Evans.
Chapman and Evans wrote up their first paper on the subject and sent it to the Journal of The
American Medical Association (JAMA). Morris Fishbein, the editor of JAMA, contacted Dr. Hertz
sharing with him that “I have a paper here from Chapman and Evans and they are saying they
have propriety of the discovery of radioiodine and your name is not even on the paper [2].”
Fishbein asked Hertz and Roberts to write up their seventh paper on the medical uses of RAI.
And so there appeared side by side in JAMA May 11, 1946, two articles from the same hospital
using RAI describing the successful treatment of hyperthyroidism (Figure 8a and b) [3, 4].
Dr. James Thrall, Chairman Emeritus MGH Department of Radiologist, stated on April 5, 2016,
that “Chapman and Evans had basically stolen his (Hertz’s ) work … the most flagrant, I think,
unethical academically reprehensible behavior…worst yet, Saul Hertz died at 44 years old in
1950 and theses two gentlemen (Chapman and Evans) spent a great deal of time and effort
rewriting history [5].”
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Hertz strongly encouraged the U.S. Atomic Energy Commission to distribute RAI off of the
atomic pile. In August 1946, this service began and I-131 was used exclusively because it was
much less expensive. Going forward RAI became the preferred method of treating “Graves”
disease worldwide (Figure 7).
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Figure 8. (a) JAMA: May 11, 1946 MGH's Saul Hertz/MIT's Arthur Roberts VII. The use of radioactive iodine therapy
in hyperthyroidism and (b) JAMA: May 11, 1946 MGH's Earl Chapman/MIT's Robley Evans the treatment of hyper‐
thyroidism with radioactive iodine. Documentation of unethical publishing practices…stolen intellectual property.
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2.2. RAI: the first and gold standard of targeted cancer therapy
Dr. Hertz responded to MGH’s Director, Dr. Paxton’s letter on March 12, 1946, “It is a
coincidence that my new research project is in Cancer of the Thyroid which I believe holds the
key to the larger problem of Cancer in general.” The next day March 13, 1946, Hertz writes to
MIT President Compton, “I have certain ideas in the field of Cancer of the Thyroid which are
even more intriguing from a physician’s point of view than the cure of Graves’ disease with
Radioactive Iodine without operation….the cancer field is relatively virgin territory both from
the standpoint of actual knowledge or prognostic attack.” Hertz goes on in the same corre‐
spondence to make note, “Only recently a group of workers in England have reported the
regular production of Cancer of the Thyroid in animals by a series of steps which are subject
to analysis by means of RAI as a tracer. The relationship of this project to the one on Graves’
disease will be evident to you.”
Figure 9. The American Weekly June 2, 1946 Dr Hertz states, "…demand is expected for radioactive iodine and as re‐
search develops in the field of cancer and leukemia for other radioactive medicines.".
The American Weekly, June 2, 1946, quoted Dr. Hertz as stating, “…demand is expected for
radioactive iodine and as research develops in the fields of cancer and leukemia for radioactive
medicines” (Figure 9).
On September 9, 1946, The Radioactive Isotope Research Fund was registered in Boston,
Massachusetts. The Fund established The Radioactive Isotope Research Institute with Clinical
and Laboratory facilities on Commonwealth Avenue in Boston and on 5th Avenue in New
York City. Dr. Hertz reached out to Montefiore Hospital’s Dr. S.M. Seidlin to be the Associative
Director. His brother Dr. Roy Hertz was the oncologist. Roy Hertz went on to The National
Institutes of Health after his brother Saul’s death to win a Lasker Award. Dr. Eugene Nelson
was the Physicist (Figure 10).
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Figure 10. September 9, 1946 announcement of the world's first Radioactive Isotope Institute. Dr Saul Hertz established
the institute and served as the director.
Figure 11. The Harvard Crimson, May 24, 1949 Hertz To Use Nuclear Fission in Cure for Cancer “&he (Hertz)empha‐
sized this example in therapeutic application as a beacon in utilizing the tracer methods employing radioactive sub‐
stances in other organs than the thyroid.”.
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Dr. Hertz while at The Beth Israel Hospital explored the use of RAI in treating thyroid cancer
patients. In a radio broadcast on Boston’s WEEI’s Yankee Network, November 18, 1948, Hertz
discussed extensively RAI treatment being used in treating thyroid cancer at The Beth Israel
Hospital.
The headline of The Harvard Crimson May 24, 1949, reads “Hertz to Use Fission in Cure for
Cancer.” In the text of the article is “Dr. Hertz feels that the application of isotope research to
the cancer problem will be along the ‘tracer’ lines, since it has been demonstrated that the
majority of cancerous thyroids do not take up the radioactive iodine in the manner in which
do the glands of patients suffering from Graves’ disease…he (Hertz) emphasized this example
in therapeutic application as a beacon in utilizing the tracer methods… (Figure 11).
Figure 12. Boston Globe August 3, 1949 "atomic cocktail" cured cancer.
Figure 12 shows Boston Globe photo of a man drinking an “atomic cocktail.”
A patient emailed this in March 2016, Treatment with radioactive iodine knocked the thyroid cancer
(metastatic to a little bit of bone and lung) right out of me, exceeding my doctor’s expectations… I am
now 81. We have a large family. Many were praying for me. The cure delivered on the wings of prayer
was Dr. Saul Hertz's discovery, the miracle of radioactive iodine. Few can equal such a powerful and
precious gift.
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